Adbry Injection, Solution
Product Images NDC 50222-350

33 FDA label images from Leo Pharma Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 33 technical images submitted to the FDA as part of the official labeling for Adbry (NDC 50222-350). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Leo Pharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure A (Tralokinumab 01)

Figure A (Tralokinumab 01)
Instructional diagram showing labeled parts of the Adbry (tralokinumab-ldrm) prefilled syringe before use including plunger head, plunger rod, finger flange, viewing window, label with expiration date, needle, needle guard clips, and needle cover. The after use image shows the used syringe with the needle guard activated. Instructions note that two injections with separate syringes are required for a full dose.*
FDA Label Image

Figure B (Tralokinumab 02)

Figure B (Tralokinumab 02)
Illustration showing the components related to Adbry (tralokinumab-ldrm) injection, solution administration. It includes two Adbry prefilled syringes, an alcohol swab, cotton balls or gauze, and a sharps container for disposal.*
FDA Label Image

Figure C (Tralokinumab 03)

Figure C (Tralokinumab 03)
An illustration showing a hand holding a rectangular box, likely representing packaging for a pharmaceutical product. The box has a triangular arrow on the surface and some text on the side, suggestive of typical product packaging instructions or labeling details.*
FDA Label Image

Figure D (Tralokinumab 04)

Figure D (Tralokinumab 04)
An instructional illustration depicting a stopwatch showing a 30-minute waiting time. The text below the stopwatch reads 'Waiting time.' This likely indicates a required wait period in a procedure or process.*
FDA Label Image

Figure E (Tralokinumab 05)

Figure E (Tralokinumab 05)
An instructional illustration showing a hand holding a syringe being removed from a tray inside a box. The image depicts the process of taking a prefilled syringe from its packaging, likely for a subcutaneous injection.*
FDA Label Image

Figure F (Tralokinumab 06)

Figure F (Tralokinumab 06)
An instructional illustration showing a hand holding a prefilled injection syringe with a labeled viewing window, and a close-up of the syringe's needle end. The drawing depicts the correct handling technique for a subcutaneous injection device.*
FDA Label Image

Figure G (Tralokinumab 07)

Figure G (Tralokinumab 07)
An anatomical illustration showing recommended injection sites for Adbry (tralokinumab-ldrm) subcutaneous injection. Shaded areas indicate that self-injection or caregiver injection can be done on the abdomen and upper thighs, while injection by caregiver only is marked for the outer upper arms.*
FDA Label Image

Figure H (Tralokinumab 08)

Figure H (Tralokinumab 08)
An instructional illustration showing a hand holding a wipe or cloth, cleaning a surface that appears to be a skin area on an arm or leg, likely demonstrating site preparation before a subcutaneous injection.*
FDA Label Image

Figure I (Tralokinumab 09)

Figure I (Tralokinumab 09)
An instructional illustration showing a hand holding a syringe with a needle cap being removed. An arrow points to the left, indicating the direction to pull off the needle cap from the syringe before use.*
FDA Label Image

Figure J (Tralokinumab 10)

Figure J (Tralokinumab 10)
An instructional illustration showing a hand holding a syringe at a 45-degree angle, positioned above an arm for subcutaneous injection. The image depicts the angle for administering an injection, relevant for products like Adbry injection solution.*
FDA Label Image

Figure K (Tralokinumab 11)

Figure K (Tralokinumab 11)
An instructional illustration showing a hand injecting a subcutaneous injection into the abdomen. The image highlights proper placement and technique for administering an injection using a syringe or injector pen, indicated by an arrow pointing to the injection site.*
FDA Label Image

Figure L (Tralokinumab 12)

Figure L (Tralokinumab 12)
An instructional illustration depicting a hand administering a subcutaneous injection with a syringe into a forearm, showing the proper injection technique for self-administration.*
FDA Label Image

Figure M (Tralokinumab 13)

Figure M (Tralokinumab 13)
An instructional illustration showing a circular arrow symbol with the word "repeat" inside, indicating a repeat action or step in a sequence. The image is simple, using black line art on a light background.*
FDA Label Image

Figure N (Tralokinumab 14)

Figure N (Tralokinumab 14)
An instructional illustration showing a hand holding a syringe and placing it into a sharps disposal container, with another syringe already inside the container. The illustration emphasizes safe disposal of used syringes, likely related to subcutaneous injection administration.*
FDA Label Image

Figure A (Tralokinumab 15)

Figure A (Tralokinumab 15)
The carton label for Adbry (tralokinumab-ldrm) Injection, 150 mg/mL per syringe, by LEO Pharma Inc. It contains two 1 mL single-dose prefilled syringes (300 mg total) for subcutaneous use only. The packaging includes storage instructions to refrigerate at 36°F to 46°F (2°C to 8°C) and features dosing and handling details alongside the NDC code 50222-346-02.*
FDA Label Image

Figure B (Tralokinumab 16)

Figure B (Tralokinumab 16)
The image shows the packaging label for Adbry (tralokinumab-ldrm) Injection, 150 mg/mL per syringe. It is a subcutaneous injection supplied in a multipack containing four 1-mL single-dose prefilled syringes, totaling 600 mg. The labeler is LEO Pharma Inc., and storage instructions include refrigeration between 2°C to 8°C in the original carton to protect from light. The package design includes a syringe illustration and the Adbry logo with decorative colored shapes.*
FDA Label Image

Figure C (Tralokinumab 17)

Figure C (Tralokinumab 17)
Black-and-white line drawing of a hand holding a rectangular box, suggesting how to hold or handle the product packaging. There are no visible text details or product identifiers visible on the box in the image.*
FDA Label Image

Figure D (Tralokinumab 18)

Figure D (Tralokinumab 18)
An instructional illustration showing a hand removing a single injection device from an open box containing multiple units arranged inside. The image demonstrates how to access the product from its packaging.*
FDA Label Image

Figure E (Tralokinumab 19)

Figure E (Tralokinumab 19)
An illustration showing a stopwatch icon indicating a waiting time of 45 minutes, with the text 'Waiting time' below the icon.*
FDA Label Image

Figure F (Tralokinumab 20)

Figure F (Tralokinumab 20)
An instructional illustration showing a hand holding an injection pen with a labeled viewing window and a section for lot and expiration information, presumably for the administration of Adbry (tralokinumab-ldrm) injection.*
FDA Label Image

Figure G (Tralokinumab 21)

Figure G (Tralokinumab 21)
An instructional diagram illustrating preferred injection sites for Adbry (tralokinumab-ldrm) subcutaneous injection. Shaded areas on the abdomen, thigh, and upper arm indicate where injections can be administered by the caregiver or by self-injection, with a key distinguishing between caregiver-only and self or caregiver injection sites.*
FDA Label Image

Figure H (Tralokinumab 22)

Figure H (Tralokinumab 22)
An instructional illustration depicting a hand holding a small rectangular object, possibly a wipe or swab, positioned against a flat surface, likely demonstrating an application or cleaning step related to drug administration or preparation.*
FDA Label Image

Figure I (Tralokinumab 23)

Figure I (Tralokinumab 23)
An instructional diagram showing a hand holding an injection pen and another hand removing the cap from the pen. An arrow indicates the direction to pull the cap off, suggesting preparation for subcutaneous injection with the Adbry injection pen device.*
FDA Label Image

Figure J (Tralokinumab 24)

Figure J (Tralokinumab 24)
An instructional illustration showing how to hold and inject a subcutaneous injection pen at a 90-degree angle into the skin, which is likely demonstrating use of the Adbry (tralokinumab-ldrm) injection.*
FDA Label Image

Figure K (Tralokinumab 25)

Figure K (Tralokinumab 25)
An instructional illustration showing a hand holding a prefilled injection device for subcutaneous administration. The diagram indicates a 15-second count while the device is pressed against the skin, demonstrating the time needed for proper injection of the solution.*
FDA Label Image

Figure L (Tralokinumab 26)

Figure L (Tralokinumab 26)
An instructional diagram illustrating the proper method for administering the Adbry injection subcutaneously. It shows a hand holding the syringe against the skin with a timer indicating a 5-second pause, accompanied by a numeric countdown from 1 to 5 seconds to guide the duration of needle contact during injection.*
FDA Label Image

Figure M (Tralokinumab 27)

Figure M (Tralokinumab 27)
Illustration showing the method of subcutaneous injection of Adbry (tralokinumab-ldrm). The image depicts a hand holding an injection device aimed at the abdominal area with an arrow indicating the direction for administration.*
FDA Label Image

Figure N (Tralokinumab 28)

Figure N (Tralokinumab 28)
An instructional illustration showing a hand holding a drug injection device with a viewing window. Two close-ups indicate the appearance of the viewing window before and after use, demonstrating that the window changes from blank to filled after administration, likely confirming dose delivery.*
FDA Label Image

Figure O (Tralokinumab 29)

Figure O (Tralokinumab 29)
An instructional illustration showing a hand holding an injection device above a sharps disposal container. The image depicts the act of discarding the injection pen into the container, indicated by a downward arrow.*
FDA Label Image

Principal Display Panel (150 mg/mL Syringe Carton)

Principal Display Panel (150 mg/mL Syringe Carton)
Packaging label for Adbry (tralokinumab-ldrm) injection, 150 mg/mL per syringe, for subcutaneous use. The carton contains two 1-mL single-dose prefilled syringes with needle guard. Labeler is LEO Pharma Inc. Storage instructions specify refrigeration at 2°C to 8°C (36°F to 46°F) to protect from light. The label includes usage and packaging details along with the product website www.ADBRY.com.*
FDA Label Image

Principal Display Panel (150 mg/mL Syringe Carton)

Principal Display Panel (150 mg/mL Syringe Carton)
Packaging label for Adbry (tralokinumab-ldrm) injection, 150 mg/mL per syringe, subcutaneous use. The label shows a multipack of four 1-mL prefilled syringes. It includes storage instructions to refrigerate at 36°F to 46°F (2°C to 8°C) and branding by LEO Pharma Inc. The carton contains dosing equivalencies and a barcode.*
FDA Label Image

Principal Display Panel (300 mg/2 mL Autoinjector Carton)

Principal Display Panel (300 mg/2 mL Autoinjector Carton)
Packaging label for Adbry (tralokinumab-ldrm) Injection 300 mg/2 mL single-dose autoinjector. The label states it is for subcutaneous use only and includes storage instructions to keep refrigerated at 36°F to 46°F (2°C to 8°C). It lists carton contents as one single-dose autoinjector, prescribing information, and instructions for use and patient information. The labeler is LEO Pharma Inc.*
FDA Label Image

Principal Display Panel (300 mg/2 mL Autoinjector Carton)

Principal Display Panel (300 mg/2 mL Autoinjector Carton)
Adbry 300 mg/2 mL injection, solution for subcutaneous use, in a single-dose autoinjector carton. The label indicates packaging contains two single-dose autoinjectors. Manufactured by LEO Pharma Inc., the label includes storage instructions and a QR code for more information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.